ArticleFrontiers in psychiatry2021
Potential of Antithrombin III as a Biomarker of Antidepressive Effect in Major Depressive Disorder.
Article in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Systematic Review and Meta-Analysis of Mass Spectrometry Proteomics Applied to Human Peripheral Fluids to Assess Potential Biomarkers of Schizophrenia.International journal of molecular sciences · 2022Pooled it
- Electroconvulsive Therapy (ECT) and Repetitive Transcranial Magnetic Stimulation (rTMS), Benefits and Adverse Effects in Patients with Depression: A Scoping Review.Journal of clinical medicine · 2026Review
- Higher neutrophil-lymphocyte ratio predicts poor response to repetetive transcranial magnetic stimulation(rTMS) in treatment resistant depression.European archives of psychiatry and clinical neuroscience · 2025Article
- Plasma vitamin D binding protein as the potential predictor of depressive disorder risk in breast cancer patients.Scientific reports · 2025Article
- Serum proteomic changes related to residual impairment in remittent depression are associated with immune and inflammatory processes.Scientific reports · 2024Article
- Association between rTMS-induced changes in inflammatory markers and improvement in psychiatric diseases: a systematic review.Annals of general psychiatry · 2024Review
- Plasma alpha-trypsin inhibitor heavy chain 4 as an age-specific biomarker in the diagnosis and treatment of major depressive disorder.Frontiers in psychiatry · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.